The excitatory amino acid receptors selectively activated by N-methyl-D-aspartate (N-Me-D-Asp) (also known as NMDA) are a major determinant of central nervous system neuronal excitability. We report here that rat brain synaptic plasma membranes contain a distinct population of and uptake sites by their sharp pH optimum, more rapid association rate, preferential localization in synaptic structures, and lack of dependence on temperature and inorganic ions. As with other receptor systems, ligand binding at the N-Me-D-Asp site is reduced by guanine nucleotides but not by adenosine nucleotides.
and uptake sites by their sharp pH optimum, more rapid association rate, preferential localization in synaptic structures, and lack of dependence on temperature and inorganic ions. As with other receptor systems, ligand binding at the N-Me-D-Asp site is reduced by guanine nucleotides but not by adenosine nucleotides. Binding is insensitive to Under conditions that selectively reveal N-Me-D-Asp receptors, these sites are found to exhibit considerable anatomical specificity as evidenced by variations within cortical, striatal, and thalamic regions. Autoradiography also showed that regions in rodent and primate brain that are especially sensitive to anoxic and excitotoxic neuronal damage (e.g., Sommer's sector or CA1) have a high level of N-Me-n-Asp sites. Since N-Me-D-Asp receptors are known to contribute to these causes of neuronal loss, their selective distribution partially accounts for the pattern of selective damage seen in these pathological conditions.
The recent discovery and characterization of the N-methyl-D-aspartate (N-Me-D-Asp) (also known as NMDA) excitatory amino acid receptor class have resulted in new insights into the physiological basis ofbrain excitability. N-Me-D-Asp receptors regulate cation conductances (Na+, K+, and Ca2+) in a voltage-dependent manner when Mg2+ is present, whereas the other excitatory amino acid receptors, kainate and quisqualate, show voltage-independent responses (1, 2). Thus, N-Me-D-Asp receptors act as a signal amplifying system along select excitatory pathways. As a consequence, N-Me-D-Asp receptor antagonists can protect the brain from seizure activity as well as neuronal loss following hypoglycemia and ischemia (3) (4) (5) (6) (7) . N-Me-D-Asp receptor antagonists also block the formation of long-term potentiation (LTP), a presumed synaptic analogue of memory (8) (9) (10) , and also block a spatial learning task (11) . Sigma opiates block both N-Me-D-Asp responses and LTP formation, but the site of interaction is unknown (12, 13) . Excitatory amino acid receptors have been shown to be influenced in various degenerative diseases (14, 15 Membrane Preparation. Membrane fractions were obtained from each step in the preparation scheme used to purify synaptic plasma membranes (SPMs) and synaptic junctions (16) . The detailed procedure is described elsewhere (17) . Each membrane fraction was lysed with 200 ,uM Tris acetate buffer (pH 7.2) and washed four times in the same buffer to remove endogenous acidic amino acids and inorganic ions. Bovine serum albumin was used as a standard for protein determination (18) .
Binding Assay. The L-[3H]glutamate binding assay used is a modification of an assay (17) in which membrane-bound radioligand is separated from free ligand by centrifugation, except in the experiments described in Fig. 2 Autoradiography. Rat brain and human hippocampal tissue sections were prepared for autoradiography as described (19) . Glutamate binding to kainate and amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) sites was prevented by the addition of 5 uM quisqualate (20) . Binding and/or uptake at uptake sites was prevented by omitting Na+ and C1-ions and by including the C1-channel blocker 4-Abbreviations: AMPA, amino-3-hydroxy-5-methyl-4-isoxazolepropionate; LTP, long-term potentiation; N-Me-D-Asp, N-methyl-Daspartate; SPMs, synaptic plasma membranes.
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RESULTS

Effects of
The antagonist profile of the N-Me-D-Asp-sensitive binding sites also supports the N-Me-D-Asp-receptor identification of this binding site. As shown in Fig. 3 Fig. 4A ). High concentrations of N-Me-D-Asp sites are found in the outer layers of cerebral cortex, the CA1 region of the hippocampus, and the caudate putamen. Under these autoradiographic conditions, one can observe a more marked anatomical specificity than that previously described using the subtractive approach (19) . For example, lamination in the neocortex is more distinct, and a heterogeneity of receptor densities becomes more noticeable in the thalamus and striatal gray matter (with greater densities in the medial portion of the striatum as well as in patches).
N-Me-D-Asp-sensitive sites in human brain display a similar anatomical localization (Fig. 4C) . High levels of binding are found in the dendritic fields of the granule and pyramidal cells of the hippocampus and in the outer layers of the cerebral cortex. Highest levels of binding were found over the exceptionally vulnerable Sommer's sector, CA1 hippocampus.
Nucleotide Inhibition of N-Me-D-Asp-Site Binding. GTP and the related derivative, guanylylimidodiphosphate, reduced binding at the N-Me-D-Asp-sensitive site when tested at concentrations of 100 ,uM ( Table 1 ). The corresponding adenosine derivatives were without substantial effect. GDP exhibited substantial activity as an inhibitor of binding, while cGMP and CTP were less effective. (Fig. 5) . Both ligand binding and electrophysiological measurements were from a dendritic field that contains one predominate type of synapse (the hippocampal CA3-CA1 synapse) and that contains the brain's highest density of N-Me-D-Asp sites (19, 28) . Given the high degree of correspondence, we conclude that the binding site probably represents the physiologically active receptor.
Comparison to Other Radioligand Binding Studies. L-[3H]Glutamate binding assessed in the presence of Cl-ions primarily appears to represent a transport site (29) (30) (31) (32) (33) . Even in the absence of Na' and Cl-ions, the majority of binding in crude membrane preparations is also N-Me-D-Asp insensitive (34, 35) . However, the results reported here show that there is a minor, yet significant, population of N-Me-D-Aspsensitive binding sites in whole brain plasma membranes, which upon further purification of synaptic structures becomes a greater percentage of the total binding. Significant levels of N-Me-D-Asp-sensitive binding are also found in purified postsynaptic densities (36) . Since N-Me-D-Aspsensitive binding in both membrane fractions ( Figs. 1 and 2 ) and autoradiographic preparations (19) is rapidly reversible, is insensitive to freeze/thaw and detergent treatment, and is not temperature dependent, radioligand labeling appears to represent true binding and not transport.
Other were made in the stratum radiatum of CA1 hippocampus using 100 ,uM phosphonate (9, 20) . Abbreviations of phosphonates are defined in the legend to Table 1. mate binding inhibition by GTP is mediated indirectly by a GTP modulatory protein, then this result would suggest that the N-Me-D-Asp receptor is coupled to a second messenger system, which is modulated by GTP. Interestingly, there have been recent demonstrations of possible second messenger mediation of N-Me-D-Asp receptor action (40) (41) (42) .
Although ketamine and the sigma opiates antagonize the actions ofN-Me-D-Asp, they are not competitive inhibitors of the N-Me-D-Asp binding site; this is in agreement with electrophysiological studies (12, 26) . Therefore, the site of ketamine interaction with the N-Me-D-Asp receptor system may be at the second messenger level or at the Ca2+/Na' channel associated with the N-Me-D-Asp receptor. Since these two systems appear to interact, it is significant that N-Me-D-Asp and sigma opiate sites exhibit nearly identical distributions and densities (19, 43, 44) .
Clinical Significance. N-Me-D-Asp antagonists block neuronal loss following ischemia and hypoglycemia and also block epileptiform activity. Therefore, it is significant that ischemia, hypoglycemia, epilepsy, and excessive glutamate infusions all selectively destroy regions of the hippocampus that have high densities of N-Me-D-Asp receptors (6, 7, (45) (46) (47) . For example, the region of the brain that is perhaps the most vulnerable to neuronal loss following sustained seizure activity or anoxia is Sommer's sector or CAl hippocampus. In both rats and humans, this region has a particularly high concentration of N-Me-D-Asp sites (Fig. 4) , thus partially accounting for the pattern of selective neuronal loss seen in these pathologies. Consequently, the expression and regulation of N-Me-D-Asp receptors may be critical for determining the distinction between plastic (e.g., LTP) and pathologic responses in the central nervous system. Accordingly, using these methods, we have recently found that hippocampal N-Me-D-Asp receptors exhibit little, if any, decrement in Alzheimer disease in the absence of severe cell loss (48) .
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